Literature DB >> 22539646

Drug-associated acute lung injury: a population-based cohort study.

Rajanigandha Dhokarh1, Guangxi Li2, Christopher N Schmickl3, Rahul Kashyap4, Jyoti Assudani4, Andrew H Limper5, Ognjen Gajic4.   

Abstract

BACKGROUND: A number of drugs have been reported as risk factors for acute lung injury (ALI) and ARDS. However, evidence is largely limited to case reports, and there is a paucity of data on the incidence and outcome of drug-associated ALI (DALI).
METHODS: Using a population-based retrospective cohort study design, critically ill patients with a diagnosis of ALI were studied. These patients were classified as having DALI or non-DALI, based on whether they were exposed to prespecified drugs prior to development of ALI. Outcomes were compared between the two groups and frequencies and incidences reported.
RESULTS: Among 514 patients with ALI, 49 (9.5%) had DALI with an estimated population-based incidence of 6.6 (95% CI, 4.8-8.5) per 100,000 person-years. Of the 49 patients with DALI,36 received chemotherapeutic/antiinflammatory agents, and 14 received amiodarone. Twelve patients had no additional risk factors for ALI (probable DALI), whereas 37 had alternative risk factors (possible DALI). Patients with and without DALI had similar baseline characteristics. However, the APACHE (Acute Physiology and Chronic Health Evaluation) III scores (median, 83 vs 70, P 5 .03), ICU mortality (35% vs 20%, P 5 .03), and hospital mortality (63% vs 32%, P , .001)were significantly higher in the DALI group compared with those of the non-DALI group. Hospital mortality remained significantly higher after adjusting for APACHE III score on admission and the presence of malignancy in logistic regression analysis (OR, 2.8; 95% CI, 1.3-6.4; P 5 .009).
CONCLUSIONS: Drugs are important risk factors for ALI, and recognizing them as such may have important implications for early identification of patients at risk, discontinuation of the offending agent, and prognosis.

Entities:  

Mesh:

Year:  2012        PMID: 22539646      PMCID: PMC3465105          DOI: 10.1378/chest.11-2103

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  22 in total

Review 1.  Drug-induced lung diseases: most common reaction patterns and corresponding high-resolution CT manifestations.

Authors:  C Isabela S Silva; Nestor L Müller
Journal:  Semin Ultrasound CT MR       Date:  2006-04       Impact factor: 1.875

Review 2.  Drug-induced pulmonary disease. An update.

Authors:  E C Rosenow; J L Myers; S J Swensen; R J Pisani
Journal:  Chest       Date:  1992-07       Impact factor: 9.410

Review 3.  Acute respiratory distress syndrome.

Authors:  Susannah K Leaver; Timothy W Evans
Journal:  BMJ       Date:  2007-08-25

Review 4.  Drug-induced noncardiogenic pulmonary edema.

Authors:  C R Reed; F L Glauser
Journal:  Chest       Date:  1991-10       Impact factor: 9.410

Review 5.  Pulmonary toxicity from novel antineoplastic agents.

Authors:  I Dimopoulou; A Bamias; P Lyberopoulos; M A Dimopoulos
Journal:  Ann Oncol       Date:  2005-11-16       Impact factor: 32.976

Review 6.  Report of the American-European Consensus conference on acute respiratory distress syndrome: definitions, mechanisms, relevant outcomes, and clinical trial coordination. Consensus Committee.

Authors:  G R Bernard; A Artigas; K L Brigham; J Carlet; K Falke; L Hudson; M Lamy; J R LeGall; A Morris; R Spragg
Journal:  J Crit Care       Date:  1994-03       Impact factor: 3.425

7.  Causes and prognosis of diffuse alveolar damage diagnosed on surgical lung biopsy.

Authors:  Joseph G Parambil; Jeffrey L Myers; Marie-Christine Aubry; Jay H Ryu
Journal:  Chest       Date:  2007-05-02       Impact factor: 9.410

8.  Amiodarone and the development of ARDS after lung surgery.

Authors:  W Van Mieghem; L Coolen; I Malysse; L M Lacquet; G J Deneffe; M G Demedts
Journal:  Chest       Date:  1994-06       Impact factor: 9.410

9.  Fatal pulmonary failure complicating high-dose cytosine arabinoside therapy in acute leukemia.

Authors:  B S Andersson; M A Luna; C Yee; K K Hui; M J Keating; K B McCredie
Journal:  Cancer       Date:  1990-03-01       Impact factor: 6.860

Review 10.  Drug-induced pulmonary disease.

Authors:  E C Rosenow; A H Limper
Journal:  Semin Respir Infect       Date:  1995-06
View more
  9 in total

1.  Acute respiratory distress syndrome mimickers lacking common risk factors of the Berlin definition.

Authors:  Aude Gibelin; Antoine Parrot; Bernard Maitre; Christian Brun-Buisson; Armand Mekontso Dessap; Muriel Fartoukh; Nicolas de Prost
Journal:  Intensive Care Med       Date:  2015-09-25       Impact factor: 17.440

2.  Surgical lung biopsy to diagnose Behcet's vasculitis with adult respiratory distress syndrome.

Authors:  Ravikanth Vydyula; Charles Allred; Mariana Huartado; Bushra Mina
Journal:  Lung India       Date:  2014-10

3.  Characteristics and Prognostic Impact of Pneumonitis during Systemic Anti-Cancer Therapy in Patients with Advanced Non-Small-Cell Lung Cancer.

Authors:  Daichi Fujimoto; Ryoji Kato; Takeshi Morimoto; Ryoko Shimizu; Yuki Sato; Mariko Kogo; Jiro Ito; Shunsuke Teraoka; Kazuma Nagata; Atsushi Nakagawa; Kojiro Otsuka; Keisuke Tomii
Journal:  PLoS One       Date:  2016-12-22       Impact factor: 3.240

4.  High-dose steroid therapy for acute respiratory distress syndrome lacking common risk factors: predictors of outcome.

Authors:  Yoshiaki Kinoshita; Hiroshi Ishii; Hisako Kushima; Kentaro Watanabe; Masaki Fujita
Journal:  Acute Med Surg       Date:  2017-10-25

5.  Clinical characteristics and prognosis of drug-associated acute respiratory distress syndrome compared with non-drug-associated acute respiratory distress syndrome: a single-centre retrospective study in Japan.

Authors:  Keisuke Anan; Kazuya Ichikado; Kodai Kawamura; Takeshi Johkoh; Kiminori Fujimoto; Moritaka Suga
Journal:  BMJ Open       Date:  2017-11-08       Impact factor: 2.692

6.  Biomarker profiles of coagulopathy and alveolar epithelial injury in acute respiratory distress syndrome with idiopathic/immune-related disease or common direct risk factors.

Authors:  Kansuke Koyama; Shinshu Katayama; Ken Tonai; Jun Shima; Toshitaka Koinuma; Shin Nunomiya
Journal:  Crit Care       Date:  2019-08-19       Impact factor: 9.097

Review 7.  Incidence and prognostic factors in severe drug-induced interstitial lung disease caused by antineoplastic drug therapy in the real world.

Authors:  Sawako Kaku; Hidehito Horinouchi; Hirokazu Watanabe; Kan Yonemori; Takuji Okusaka; Narikazu Boku; Naoya Yamazaki; Akira Kawai; Yuichiro Ohe; Masahiko Kusumoto
Journal:  J Cancer Res Clin Oncol       Date:  2022-02-07       Impact factor: 4.322

8.  Adverse reaction of methylprednisolone pulse therapy: Acute respiratory distress syndrome.

Authors:  Fereshteh Ashtari; Rasool Soltani; Shervin Shokouhi; Ali Rismanbaf; Somayeh Hajiahmadi; Atousa Hakamifard
Journal:  Clin Case Rep       Date:  2021-07-16

9.  Pulmonary Complications Secondary to Immune Checkpoint Inhibitors.

Authors:  Hasan Ahmad Hasan Albitar; Narjust Duma; Konstantinos Leventakos; Alice Gallo De Moraes
Journal:  Int J Chronic Dis       Date:  2020-04-23
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.